Noopur Raje, MD, Massachusetts General Hospital

In this episode, OncLive® speaks with Dr. Noopur Raje on developments in multiple myeloma, Dr. Ryotaro Nakamura on data related to graft-vs-host disease, and Dr. Joshua Brody on the latest in non-Hodgkin lymphoma.

Noopur Raje, MD, discusses the current challenges faced in the multiple myeloma treatment paradigm.

Noopur Raje, MD, discusses the rationale for CAR T-cell therapy in multiple myeloma.

Noopur Raje, MD, discusses future research with bispecific T-cell engagers in multiple myeloma.

Noopur Raje, MD, discusses the potential utility of belantamab mafodotin in multiple myeloma.

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, and professor of medicine, Harvard Medical School, discusses data with AMG 420 in multiple myeloma.

Noopur Raje, MD, discusses the utility of belantamab mafodotin in the treatment of patients with multiple myeloma.

Noopur Raje, MD, professor of medicine at Harvard Medical School and director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses data for the standard triplet regimens in the treatment of patients with relapsed/refractory myeloma.

Noopur Raje, MD, professor of medicine at Harvard Medical School and director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses treatment approaches for patients with relapsed/refractory multiple myeloma.

Noopur Raje, MD, professor of medicine at Harvard Medical School and director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses preliminary data on bb21217 in multiple myeloma.

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, discusses the potential of quadruplet regimens in the multiple myeloma treatment paradigm.

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, discusses the impact of bb2121 in myeloma.